Navigation Links
Cepheid Signs Group Purchasing Contract with Novation, the Nation's Largest Healthcare Contracting Organization
Date:5/20/2008

proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.

This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to product performance and utility, and future market opportunities and market size. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: unforeseen manufacturing problems; regulatory developments and practices regarding testing levels; customer and market acceptance of the product; the failure of products to perform as expected, whether due to manufacturing errors, defects or otherwise; the impact of competitive products and pricing; potentially lengthy sales cycles in some markets; reimbursement rates for the products; the fact that VHA, UHC and Provista members have no commitment to purchase any products, and there can be no assurance that they will do so in the future; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2007 and in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ include
'/>"/>

SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cepheid to Present at the Robert W. Baird Growth Stock Conference and the Bank of America Healthcare Conference
2. Cepheid Schedules Teleconference and Webcast for First Quarter 2008 Results
3. Cepheid to Present at Cowen and Companys 28th Annual Healthcare Conference
4. Cepheid Reports Fourth Quarter and Full Year 2007 Results
5. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
6. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
7. Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
8. Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
9. Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference
10. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
11. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that the Company closed ... Oracle Investment Management, Jack W. Schuler , ... proceeds were $10.5 million, before offering expenses.  The ... general corporate purposes. Under the terms ...
(Date:12/24/2014)... 23, 2014 SoundConnect’s ... designed to introduce cutting edge communication technology, ... partners of platform upgrades. This webinar series ... users in their quest to leverage web ... According to SoundConnect’s Marketing Manager, Seanna Baumgartner, ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 The report ... at 19.7% by 2019. It also provides a carefully ... strategies and challenges for the market. , Full Copy ... the report, the global market for cell expansion will ... future. It expects this growth to be driven by ...
(Date:12/24/2014)... 2014 Sigma-Aldrich Corporation (NASDAQ: ... under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) ... 22, 2014, thereby completing the U.S. HSR Act ... of the Company by Merck KGaA, Darmstadt, Germany.  ... condition to closing the transaction, which remains subject ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3
... /PRNewswire/ - IntelliPharmaCeutics Ltd. (Delaware),is pleased to ... pilot,clinical trial for its new abuse-resistant, alcohol-resistant ... IntelliPharmaCeutics,Corp. of Toronto ("IntelliPharmaCeutics" or the "Company"). ... for its novel ReXista(TM) abuse and,alcohol resistant ...
... International,Corporation ("PAREXEL") (Nasdaq: PRXL ) today announced ... the clinical pharmacology business of,Synchron Research in Ahmedabad, ... bioanalytical laboratory in Poitiers, France to a subsidiary ... of the new agreement, PAREXEL,s ownership interest in,the ...
... Core Informatics announces,that it has completed a ... System (LIMS) product, the "Core LIMS",for Progenics ... biopharmaceutical,company located in Tarrytown, NY. As part ... from its previous data management system.,The newly ...
Cached Biology Technology:IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone 2IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone 3PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France 2PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France 3PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France 4
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, ... announced it is seeing a staggering demand from its ... demand, the Company revealed, is not solely coming from ... industries as well. "A wearable is only ... a result, accuracy is the ultimate driver in long-term ...
(Date:12/10/2014)... , Dec. 9, 2014 CIE San ... catalyst that provides the connective tissue that enhances care ... them to easily share client-level information; earned a second ... expand to organizations serving seniors aging in community and; ... partner on December 11 th 4-6p. ...
(Date:12/10/2014)... December 9, 2014   ... Platform   Jifflenow, ... scheduling solutions for business-to-business (B2B) events, today announced ... in mobile near-field communication (NFC), Bluetooth low energy ... (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... for Agricultural Research and Development, and the company FARMARABA ... produce Omega 3 using marine plant micro-organisms. The ultimate ... highly valued fatty acid, and then apply them at ... centre, which has proven experience in the biotechnology and ...
... Children living near toxic waste sites in ... Indonesia may experience higher blood lead levels, resulting in a ... retardation, according to a study presented today by Kevin Chatham-Stephens, ... Medicine at Mount Sinai, at the Pediatric Academic Societies (PAS) ...
... than two million people in the United States suffer ... abnormal nerve cell firing in the brain which often ... therapies reduce seizures in about two-thirds of patients, the ... therapy and those who take drugs can experience harmful ...
Cached Biology News:Neiker-Tecnalia and FARMARABA produce Omega 3 using marine plant micro-organisms 2Children living near toxic waste sites experience higher blood lead levels resulting in lower IQ 2
... represents the state-of-the-art in permanent mounting ... permanent preservation of immunohistochemical organic insoluble ... Red, New Fuchsin, and any other ... tissue sections. Clarin can be used ...
... pLivSelect is a direct ... recombinant identification. Recombinant selection ... survival, eliminating the need ... This quick and inexpensive ...
... Express is the first fully automated proteomics ... transfer operations with complete data tracking. It ... colony picking through final protein expression and ... of delivering a plate to any of ...
... OLIGO is a multi-functional program ... oligonucleotides from a sequence file ... DNA sequencing, site-directed mutagenesis, and ... hybridization temperature and secondary structure ...
Biology Products: